{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:12:52Z","timestamp":1747163572711,"version":"3.40.5"},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.japh.2024.102128","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T18:52:04Z","timestamp":1716490324000},"page":"102128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Opportunities for de-escalation of aspirin therapy in patients with atrial fibrillation at high stroke risk receiving direct oral anticoagulants"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5037-4321","authenticated-orcid":false,"given":"Angela","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Brock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Glover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.japh.2024.102128_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/11592410-000000000-00000","article-title":"Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation","volume":"11","author":"Deedwania","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"issue":"46","key":"10.1016\/j.japh.2024.102128_bib2","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1093\/eurheartj\/ehz823","article-title":"Antithrombotic therapy after acute coronary syndrome and\/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot","volume":"40","author":"Lopes","year":"2019","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.japh.2024.102128_bib3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/jama.2022.4983","article-title":"Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement","volume":"327","author":"Davidson","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.japh.2024.102128_bib4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.japh.2024.102128_bib5","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.japh.2024.102128_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11606-007-0116-5","article-title":"Gender differences in aspirin use among adults with coronary heart disease in the United States","volume":"22","author":"Opotowsky","year":"2007","journal-title":"J\u00a0Gen Intern Med"},{"issue":"1","key":"10.1016\/j.japh.2024.102128_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/europace\/euz259","volume":"22","author":"Potpara","year":"2020","journal-title":"Europace"},{"issue":"16","key":"10.1016\/j.japh.2024.102128_bib8","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.japh.2024.102128_bib9","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.japh.2024.102128_bib10","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.japh.2024.102128_bib11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124001481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124001481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T05:44:33Z","timestamp":1730958273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319124001481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1544319124001481"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2024.102128","relation":{},"ISSN":["1544-3191"],"issn-type":[{"type":"print","value":"1544-3191"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunities for de-escalation of aspirin therapy in patients with atrial fibrillation at high stroke risk receiving direct oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2024.102128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102128"}}